Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 18/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049074 | 0.91 | CDK8 (0.50) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4051773 | 0.90 | EEF2K (0.54) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4046258 | 0.82 | MAPT (0.69) | EEF2KKDM4ENPC1MAPTHTT | |
| SCHEMBL4052293 | 0.81 | KDM4E (0.53) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4047805 | 0.79 | EEF2K (0.50) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4052747 | 0.79 | KDM4E (0.58) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4051300 | 0.77 | KDM4E (0.71) | EEF2KKDM4ENPC1MAPTHTT | |
| SCHEMBL4048241 | 0.76 | HTT (0.47) | EEF2KCDK8CDK19KDM4ENPC1 | |
| SCHEMBL4046385 | 0.75 | KDM4E (0.59) | EEF2KKDM4ENPC1MAPTHTT | |
| SCHEMBL4045460 | 0.75 | KDM4E (0.59) | EEF2KKDM4EMAPTHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819710-B1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | PNPO, PDE4A, DPYD | EEF2K 4335/4885CDK8 1482/4885CDK19 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.